Sickle cell disease
Drug research and approvals for sickle cell disease: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 16, 2026, 166 studies of sickle cell disease are recruiting on ClinicalTrials.gov, Health Canada has authorized 34 drug trials for it since 2013, FDA has 8 approved and 61 open orphan designations naming it, and the EU has 1 authorised medicine for it.
- Recruiting worldwide: 166
- Trials authorized in Canada: 34
- FDA orphan approvals: 8
- EU medicines: 1
Recruiting Now
Newest start dates first, of 166 recruiting on ClinicalTrials.gov ↗- Efficacy and Safety of SIL-8301 for Control of Hemolysis in a Uniform Sickle Cell Disease EndotypeNCT07282210 · Phase 2 · Biossil Inc. · starts Nov 1, 2026
- Virtual Reality for SCD VOCNCT07674277 · Not applicable · University of Maryland, Baltimore · starts Nov 1, 2026
- Universal Newborn Screening For Sickle Cell Disease In MozambiqueNCT07719972 · Not applicable · St. Jude Children's Research Hospital · starts Sep 24, 2026
- Haploidentical Donor Hematopoietic Cell Transplant for Sickle Cell DiseaseNCT07616154 · Phase 2 · St. Jude Children's Research Hospital · starts Sep 10, 2026
- Sub-dissociative Dose Ketamine in Treatment of Vaso-occlusive Pain Event in Children and Young AdultsNCT07369024 · Phase 2 · Mohsen Saidinejad · starts Sep 10, 2026
- Assessing Molecular Mechanisms and Effects of Music Therapy in Youth With Sickle Cell Disease Using Single-cell…NCT07562451 · Not applicable · Emory University · starts Sep 1, 2026
- Hematopoietic Stem Cell BCL11A Enhancer Gene Editing for Sickle Cell DiseaseNCT07708350 · Phase 1 · Daniel Bauer · starts Aug 1, 2026
- Early Life Exposures Among Children With Sickle Cell DiseaseNCT05377372 · Not applicable · University of Alabama at Birmingham · starts Aug 1, 2026
- Escalating Doses of VAS-101 in Subjects With Stable Sickle Cell DiseaseNCT07566494 · Phase 1 · National Heart, Lung, and Blood Institute (NHLBI) · starts Jul 31, 2026
- Integrating Point of Care Testing (POCT) For Newborn Screening and Early Care for Sickle Cell Disease in Yopougon, Côte…NCT07488520 · Phase 4 · Swiss Tropical & Public Health Institute · starts Jul 27, 2026
Trials Authorized in Canada
The 10 newest of 34; search them all in Canada trials| Sep 4, 2026 | A phase 3, double-blind, randomized, placebo-controlled, multicenter study to evaluate the effect of mitapivat on transfusion burden in subjects with sickle…MITAPIVAT (AG-348) | Agios Pharmaceuticals | Pending |
| Feb 4, 2026 | Phase 2a, multicenter, randomized, doubleblind, placebo-controlled study to assess the safety of anumigilimab (csl324) in adults with sickle cell diseaseCSL324 (ANUMIGILIMAB) | CSL | Closed |
| Dec 9, 2025 | A phase 2/3 randomized, multicenter study of osivelotor administered orally to adult and adolescent participants with sickle cell diseaseOSIVELOTOR (PF-07940367, GBT021601) | Pfizer | Pending |
| Sep 24, 2025 | A multicenter, randomized, double-blind, placebo-controlled study with an open-label extension to determine efficacy and safety of sil-8301 in sickle cell…SENICAPOC (SIL-8301) | BIOSSIL INC. | Ongoing |
| Apr 14, 2025 | A phase 2, double-blind, randomized, placebo-controlled, multicenter, dose-finding, efficacy, and safety study of tebapivat in participants with sickle cell…TEBAPIVAT (AG-946) | Agios Pharmaceuticals | Ongoing |
| Dec 6, 2024 | A phase 2 / phase 3, multicenter, randomized, multiple-dose, double-blind, placebo-controlled adaptive study to evaluate the safety, efficacy, and…CSL889 | CSL | Pending |
| Jul 31, 2024 | An open-label mechanistic study to assess the pharmacokinetics, pharmacodynamics and safety of orally administered epeleuton in patients with sickle cell…EPELEUTON (DS102) | AFIMMUNE LIMITED | Closed |
| Dec 29, 2022 | An open-label extension study to evaluate the long-term safety of gbt021601 administered to participants with sickle cell disease who have participated in a…GBT021601 | Pfizer | Closed |
| Nov 2, 2022 | A phase 2a, randomized, open-label study to evaluate multiple dosing regimens of subcutaneous alxn1820 in adult patients with sickle cell diseaseALXN1820 | AstraZeneca Pharmaceuticals LP | Ongoing |
| Aug 5, 2022 | A 2-part, phase 1, multicenter, single-dose, open-label study to evaluate the safety, tolerability, and pharmacokinetics of csl889 in adult patients with…CSL889 | CSL | Pending |
FDA Orphan Designations
Approved first, then open designations, newest first; 15 of 69| Jul 1, 2026 | Casgevytreatment of patients aged 2 years and older with sickle cell disease (SCD) with recurrent vaso-occlusive crises | Vertex Pharmaceuticals Inc. | Approved |
| Dec 8, 2023 | Casgevytreatment of sickle cell disease (SCD) in patients 12 years and older with recurrent vaso-occlusive crises (VOCs) | Vertex Pharmaceuticals Inc. | Approved |
| Dec 8, 2023 | Lyfgeniatreatment of patients 12 years of age or older with sickle cell disease and a history of vaso-occlusive events | Genetix Biotherapeutics Inc. | Approved |
| Dec 17, 2021 | Oxbrytatreatment of sickle cell disease (SCD) in adults and pediatric patients 4 years of age and older | Global Blood Therapeutics, Inc. | Approved |
| Nov 25, 2019 | OxbrytaOXBRYTA is indicated for the treatment of sickle cell disease (SCD) in adults and pediatric patients 12 years of age and older. | Global Blood Therapeutics, Inc. | Approved |
| Nov 15, 2019 | ADAKVEOADAKVEO® is indicated to reduce the frequency of vasoocclusive crises (VOCs) in adults and pediatric patients aged 16 years and older with… | Novartis Pharmaceuticals Corporation | Approved |
| Dec 21, 2017 | SiklosTo reduce the frequency of painful crises and to reduce the need for blood transfusions in pediatric patients, 2 years of age and older,… | Theravia Pharma | Approved |
| Jul 7, 2017 | EndariTo reduce the acute complications of sickle cell disease in adult and pediatric patients 5 years of age and older. | Emmaus Medical, Inc. | Approved |
| Oct 6, 2026 | small-molecule activator of nuclear factor erythroid…treatment of sickle cell disease | vTv Therapeutics LLC | Designated |
| Feb 19, 2026 | tebapivattreatment of sickle cell disease | Agios Pharmaceuticals, Inc. | Designated |
| Feb 4, 2026 | desidustatTreatment of Sickle Cell Disease | Zydus Healthcare (USA), LLC, | Designated |
| Jun 23, 2025 | fetal hemoglobin activator cereblon (CRBN) E3…treatment of sickle cell disease | Bristol-Myers Squibb | Designated |
| Jun 9, 2025 | (lE, 6E)-1,7-bis(4-hydroxy-3-methoxyphenyl)-1,6-…treatment of sickle cell disease | Vascarta Inc. | Designated |
| May 30, 2025 | autologous CD34+ cell therapy comprised of hematopoietic…treatment of sickle cell disease | Beam Therapeutics | Designated |
| May 15, 2025 | rilzabrutinibtreatment of sickle cell disease (SCD) | Sanofi US Services Inc. | Designated |
Medicines Authorised in the EU
Newest first| Authorised | Medicine | Holder | EPAR |
|---|---|---|---|
| Jul 1, 2019 | Xromihydroxycarbamide | Lipomed GmbH | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA